Related Experiment Videos
Circulating soluble Fas ligand correlates with disease activity in Graves' hyperthyroidism
Chih-Yuan Wang1, Wen-Bin Zhong, Tien-Chun Chang
1Graduate Institute of Physiology, and the Division of Endocrinology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Metabolism: Clinical and Experimental
|May 31, 2002
Summary
Graves' disease (GD) patients have higher levels of soluble Fas (sFas) and soluble Fas ligand (sFasL) compared to those in remission. Increased sFasL correlates with disease activity, suggesting it may indicate GD progression or regression.
Area of Science:
- Endocrinology
- Immunology
- Cell Biology
Background:
- Apoptosis, or programmed cell death, is implicated in autoimmune thyroiditis.
- The Fas/Fas ligand (FasL) pathway is crucial for immune regulation in thyroid diseases like Graves' hyperthyroidism (GD).
- Soluble Fas (sFas) acts as an apoptotic inhibitor, while soluble FasL (sFasL) can induce apoptosis.
Purpose of the Study:
- To investigate the role of circulating sFas and sFasL in modulating GD disease activity.
- To examine the relationship between sFas/sFasL levels and anti-thyrotropin-stimulating hormone receptor antibodies (TRAb) in GD patients.
Main Methods:
- Serum samples were collected from 22 untreated hyperthyroid GD patients (Group I) and 22 treated euthyroid GD patients in remission (Group II).
- Circulating levels of sFas and sFasL were measured using immunoassays.
- Statistical analysis was performed to compare levels between groups and correlate with TRAb activity.
Main Results:
- Significantly higher levels of sFas were observed in Group I (1.56 ng/mL) compared to Group II (0.76 ng/mL).
- Significantly higher levels of sFasL were found in Group I (0.153 ng/mL) compared to Group II (0.126 ng/mL).
- A significant positive correlation (r=0.69, P<.01) was found between sFasL levels and TRAb activity in all GD patients.
Conclusions:
- Elevated circulating sFas and sFasL levels are associated with active Graves' hyperthyroidism.
- Increased serum sFasL may contribute to thyroid homeostasis in GD patients.
- Serum sFasL could serve as a potential biomarker for assessing GD disease activity and progression.